PROCEPT BioRobotics to report Q4 2025 results on February 24, 2026, and host investor day on February 25, 2026.
Quiver AI Summary
PROCEPT BioRobotics Corporation announced that it will release its financial results for the fourth quarter of 2025 on February 24, 2026, followed by a conference call with management at 4:30 p.m. Eastern Time. The company will also hold an in-person investor day on February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with pre-registration encouraged. Both events will be available for live streaming and will be archived on the company's website for 90 days. PROCEPT BioRobotics focuses on advancing urological care with its AQUABEAM® and HYDROS® robotic systems, which aim to provide effective treatment for benign prostatic hyperplasia (BPH), a common condition affecting millions of men.
Potential Positives
- The announcement of an in-person investor day event indicates the company's commitment to transparency and investor relations, which may enhance shareholder confidence.
- PROCEPT BioRobotics is advancing innovative surgical technology, specifically with its AI-powered HYDROS Robotic System, positioning itself as a leader in the urology market.
- By focusing on a significant health issue affecting approximately 40 million men in the United States, the company is addressing a substantial market opportunity, which may attract further investment and interest.
Potential Negatives
- Announcement of the financial results reporting date may imply that the company is currently under scrutiny or pressure to deliver positive outcomes, which could indicate weaker performance expectations.
- Emphasis on the need for registration to attend the investor day event may signal limited capacity or high demand, raising concerns about accessibility for all interested investors.
FAQ
What is the date of PROCEPT BioRobotics' fourth quarter financial results report?
PROCEPT BioRobotics will report its fourth quarter financial results on February 24, 2026.
When will the investor day event take place?
The investor day event is scheduled for February 25, 2026, at the NASDAQ Headquarters in New York City.
How can I register for the investor day event?
Guests can register in advance by clicking the registration link provided in the press release.
Will there be a webcast for the financial results conference call?
Yes, a live webcast of the conference call will be available on the Company's website.
What are the main products offered by PROCEPT BioRobotics?
PROCEPT BioRobotics offers the AQUABEAM® and HYDROS® Robotic Systems for BPH treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRCT Insider Trading Activity
$PRCT insiders have traded $PRCT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PRCT stock by insiders over the last 6 months:
- FREDERIC H MOLL purchased 20,000 shares for an estimated $785,138
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRCT Revenue
$PRCT had revenues of $83.3M in Q3 2025. This is an increase of 42.76% from the same period in the prior year.
You can track PRCT financials on Quiver Quantitative's PRCT stock page.
$PRCT Hedge Fund Activity
We have seen 136 institutional investors add shares of $PRCT stock to their portfolio, and 130 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. added 1,262,928 shares (+58.6%) to their portfolio in Q3 2025, for an estimated $45,073,900
- CHICAGO CAPITAL, LLC added 999,873 shares (+175.7%) to their portfolio in Q3 2025, for an estimated $35,685,467
- AXA S.A. removed 850,490 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $30,353,988
- ARROWMARK COLORADO HOLDINGS LLC added 786,094 shares (+229.7%) to their portfolio in Q3 2025, for an estimated $28,055,694
- MACKENZIE FINANCIAL CORP added 745,778 shares (+105.2%) to their portfolio in Q3 2025, for an estimated $26,616,816
- UBS GROUP AG added 532,530 shares (+129.3%) to their portfolio in Q3 2025, for an estimated $19,005,995
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 524,766 shares (+34.3%) to their portfolio in Q3 2025, for an estimated $18,728,898
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRCT Analyst Ratings
Wall Street analysts have issued reports on $PRCT in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 12/18/2025
- UBS issued a "Buy" rating on 12/12/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- Oppenheimer issued a "Outperform" rating on 09/02/2025
- Piper Sandler issued a "Overweight" rating on 08/07/2025
- Wells Fargo issued a "Overweight" rating on 08/07/2025
To track analyst ratings and price targets for $PRCT, check out Quiver Quantitative's $PRCT forecast page.
$PRCT Price Targets
Multiple analysts have issued price targets for $PRCT recently. We have seen 8 analysts offer price targets for $PRCT in the last 6 months, with a median target of $50.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $47.0 on 12/18/2025
- Danielle Antalffy from UBS set a target price of $62.0 on 12/12/2025
- Craig Bijou from B of A Securities set a target price of $38.0 on 12/08/2025
- Patrick Wood from Morgan Stanley set a target price of $51.0 on 12/02/2025
- Joshua Jennings from TD Cowen set a target price of $50.0 on 11/05/2025
- Matt O'Brien from Piper Sandler set a target price of $50.0 on 11/05/2025
- Nathan Treybeck from Wells Fargo set a target price of $51.0 on 11/05/2025
Full Release
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026 . The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time .
The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time . Guests are encouraged to register in advance by clicking HERE . Registration is recommended to secure your spot.
A live webcast of both events, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com . Each webcast will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
[email protected]
